Immune mechanisms and shared immune targets in neurodegenerative diseases

被引:1
|
作者
Weiner, Howard L. [1 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; REGULATORY T-CELLS; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MOUSE MODEL; CHEMOKINE RECEPTOR 2; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROGRESSIVE MULTIPLE-SCLEROSIS; CEREBRAL MICROGLIAL ACTIVATION; MYELOID DENDRITIC CELLS; MYELIN BASIC-PROTEIN;
D O I
10.1038/s41582-024-01046-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The immune system plays a major part in neurodegenerative diseases. In some, such as multiple sclerosis, it is the primary driver of the disease. In others, such as Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease, it has an amplifying role. Immunotherapeutic approaches that target the adaptive and innate immune systems are being explored for the treatment of almost all neurological diseases, and the targets and approaches are often common across diseases. Microglia are the primary immune cells in the brain that contribute to disease pathogenesis, and are consequently a common immune target for therapy. Other therapeutic approaches target components of the peripheral immune system, such as regulatory T cells and monocytes, which in turn act within the CNS. This Review considers in detail how microglia, monocytes and T cells contribute to the pathogenesis of multiple sclerosis, Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease, and their potential as shared therapeutic targets across these diseases. The microbiome is also highlighted as an emerging therapeutic target that indirectly modulates the immune system. Therapeutic approaches being developed to target immune function in neurodegenerative diseases are discussed, highlighting how immune-based approaches developed to treat one disease could be applicable to multiple other neurological diseases.
引用
收藏
页码:67 / 85
页数:19
相关论文
共 50 条
  • [21] Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
    Dai, Lijun
    Zou, Li
    Meng, Lanxia
    Qiang, Guifen
    Yan, Mingmin
    Zhang, Zhentao
    MOLECULAR NEUROBIOLOGY, 2021, 58 (05) : 2183 - 2201
  • [22] Adipokines as targets in musculoskeletal immune and inflammatory diseases
    Gonzalez-Rodriguez, Maria
    Ruiz-Fernandez, Clara
    Cordero-Barreal, Alfonso
    Ait Eldjoudi, Djedjiga
    Pino, Jesus
    Farrag, Yousof
    Gualillo, Oreste
    DRUG DISCOVERY TODAY, 2022, 27 (11)
  • [23] Immune mechanisms in interstitial lung diseases
    Semenzato, G
    Adami, F
    Maschio, N
    Agostini, C
    ALLERGY, 2000, 55 (12) : 1103 - 1120
  • [24] IMMUNE-MECHANISMS IN NONINFLAMMATORY DISEASES
    RICHMAN, DP
    QUN, X
    FAIRCLOUGH, RH
    ARCHIVES OF NEUROLOGY, 1988, 45 (11) : 1280 - 1280
  • [25] Immune mechanisms in degenerative eye diseases
    Perez, Victor L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [26] Eosinophilic esophagitis: Immune mechanisms and therapeutic targets
    Khokhar, Dilawar
    Marella, Sahiti
    Idelman, Gila
    Chang, Joy W.
    Chehade, Mirna
    Hogan, Simon P.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (10): : 1142 - 1156
  • [27] Immune Mechanisms and Novel Targets in Rheumatoid Arthritis
    Venuturupalli, Swamy
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (02) : 301 - +
  • [28] Aging of the Immune System Mechanisms and Therapeutic Targets
    Weyand, Cornelia M.
    Goronzy, Joerg J.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 : S422 - S428
  • [29] Shared pathogenetic mechanisms of neurodegeneration between MS, stroke and neurodegenerative diseases
    Lassmann, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S201 - S201
  • [30] Mechanisms of action of intravenous immune globulin in immune-mediated diseases
    Mouthon, L
    Kaveri, SV
    Spalter, SH
    LacroixDesmazes, S
    Lefranc, C
    Desai, R
    Kazatchkine, MD
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 : 3 - 9